These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 16498577)

  • 1. Letter 1: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Wille-Jorgensen P
    Br J Surg; 2006 Mar; 93(3):374; author reply 375-6. PubMed ID: 16498577
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter 3: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Agnelli G; Bergqvist D; Dahl O; Eriksson B; Rud Lassen M; Mouret P; Rosencher N
    Br J Surg; 2006 Mar; 93(3):375; author reply 375-6. PubMed ID: 16498579
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter 2: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Tangelder MJ; Bylock A; Held P
    Br J Surg; 2006 Mar; 93(3):374-5; author reply 375-6. PubMed ID: 16498578
    [No Abstract]   [Full Text] [Related]  

  • 4. Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations.
    Rosencher N
    Anaesthesia; 2004 Aug; 59(8):803-10. PubMed ID: 15270973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ximelagatran for prevention and treatment of venous thromboembolism.
    Kwok L; Boucher M
    Issues Emerg Health Technol; 2004 Jun; (57):1-4. PubMed ID: 15214359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery.
    Cohen AT; Hirst C; Sherrill B; Holmes P; Fidan D
    Br J Surg; 2005 Nov; 92(11):1335-44. PubMed ID: 16237737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with ximelagatran in orthopaedic surgery.
    Eriksson B
    Drugs; 2004; 64 Suppl 1():27-35. PubMed ID: 15586625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.
    Koscielny J; Kiesewetter H; Jörg I; Harenberg J
    Clin Appl Thromb Hemost; 2007 Jul; 13(3):299-307. PubMed ID: 17636192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
    Eriksson H; Lundström T; Wåhlander K; Clason SB; Schulman S;
    Thromb Haemost; 2005 Sep; 94(3):522-7. PubMed ID: 16268466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ximelagatran for treatment of venous thromboembolism].
    Harenberg J; Fenyvesi T; Jörg I
    Hamostaseologie; 2002 Aug; 22(3):25-9. PubMed ID: 12215758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials of new anticoagulants.
    Anderson J; O'Donnell M
    Vnitr Lek; 2006 Mar; 52 Suppl 1():123-6. PubMed ID: 16637460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New ways to prevent venous thromboembolism--the pentasaccharide fondaparinux and the thrombin inhibitor ximelagatran--a review.
    Bergqvist D
    Acta Chir Belg; 2005 Feb; 105(1):35-9. PubMed ID: 15790200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?
    Ferretti G; Bria E; Giannarelli D; Carlini P; Felici A; Mandala M; Papaldo P; Nistico C; Fabi A; Cuppone F; Gelibter A; Terzoli E; Cognetti F
    J Clin Oncol; 2005 Oct; 23(28):7248-50; author reply 7250. PubMed ID: 16192623
    [No Abstract]   [Full Text] [Related]  

  • 14. [Prevention of venous thromboembolism in internal medicine and neurology].
    Malý J; Dulícek P; Penka M; Malý R; Gumulec J
    Vnitr Lek; 2006 Mar; 52 Suppl 1():63-7. PubMed ID: 16637452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of venous thromboembolism and long-term prevention of recurrence: present treatment options and ximelagatran.
    Eriksson H
    Drugs; 2004; 64 Suppl 1():37-46. PubMed ID: 15586626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis against venous thromboembolism after surgery for cancer.
    Moulias S; Bouchon JP; Meaume S
    N Engl J Med; 2002 Jul; 347(3):220; author reply 220. PubMed ID: 12124417
    [No Abstract]   [Full Text] [Related]  

  • 17. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of venous thromboembolism after neurosurgery.
    Agnelli G
    Thromb Haemost; 1999 Aug; 82(2):925-30. PubMed ID: 10605805
    [No Abstract]   [Full Text] [Related]  

  • 19. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran.
    Harenberg J; Jörg I; Weiss C
    Int J Toxicol; 2006; 25(3):165-9. PubMed ID: 16717032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of venous thromboembolism among hospitalized medical patients.
    Goldhaber SZ; Turpie AG
    Circulation; 2005 Jan; 111(1):e1-3. PubMed ID: 15630031
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.